A Study to Evaluate the Efficacy and Safety of Seletracetam in Adult Patients With Refractory Partial Onset Seizures

A Phase IIb/III, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Seletracetam as Adjunctive Treatment in Subjects (≥16 to 70 Years Old) With Refractory Partial Onset Seizures.

This study will evaluate the effectiveness and safety of seletracetam when it is used in addition to other anti-epileptic medications by patients with partial onset seizures. It will also help to determine the best dose to use.

Inclusion Criteria:

• Subjects from 16 to 70 years old
• Confirmed diagnosis of focal epilepsy
• Partial seizures uncontrolled while taking 1 or 2 AEDs
• At least 8 partial seizures during the 8-week baseline period

Exclusion Criteria:

• Seizures occurring only in clusters
• Status epilepticus within 1 year
• Progressive CNS disorder
• Other serious or uncontrolled diseases